



Please review the Supplemental Files folder to review documents not compiled in the PDF.

Interferon Beta-1a ring prophylaxis to reduce household transmission of SARS-CoV-2

Journal:	<i>New England Journal of Medicine</i>
Manuscript ID	Draft
Article Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Castro-Rodriguez, Jose; Pontifical Catholic University of Chile, Pediatrics Fish, Eleanor; Toronto General Research Institute, University Health Network; University of Toronto, Immunology Kollmann, Tobias; Telethon Kids Institute; Perth Children's Hospital, Infectious Diseases Iturriaga, Carolina; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology Karpievitch, Yulia; Telethon Kids Institute; The University of Western Australia, School of Biomedical Sciences Shannon, Casey; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation Chen, Virginia; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation Balshaw, Robert; University of Manitoba College of Medicine, George and Fay Yee Centre for Healthcare Innovation Ben Othman, Rym; Telethon Kids Institute Montgomery, Samuel; Telethon Kids Institute, Aniba, Radhouana; Telethon Kids Institute Ho, Joseph; Telethon Kids Institute Gidi-Yunge, Fancisca; Pontifical Catholic University of Chile, School of Dentistry Hartnell, Lucy; Telethon Kids Institute Perez-Mateluna, Guillermo; Pontifical Catholic University of Chile, Department of Pediatric Infectious Diseases and Immunology Urzúa, Marcela; Pontifical Catholic University of Chile, Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina Tebbutt, Scott; UBC; The University of British Columbia Centre for Heart Lung Innovation Garcia-Huidobro, Diego; Pontifical Catholic University of Chile, Department of Family Medicine; University of Minnesota Twin Cities, Department of Family Medicine and Community Health Perret, Cecilia; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology Borzutzky, Arturo; Pontificia Universidad Católica de Chile, Pediatric Infectious Diseases and Immunology Stick, Stephen; Telethon Kids Institute, Wal-yan Respiratory Research Centre; The University of Western Australia, Centre for Child Health Research; Perth Children's Hospital, Respiratory and Sleep Medicine</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:	<p>Background Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFNβ-1 could reduce SARS-CoV-2 household transmission.</p> <p>Methods A household cluster randomized controlled study of IFNβ-1 administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years compared to standard care, was conducted. Following randomization participants received IFNβ-1 on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household contacts.</p> <p>Results In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFNβ-1 and 565 to standard care. Based on intention to treat and per protocol analyses, IFNβ-1 treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFNβ-1 reduced household transmission.</p> <p>Conclusion Ring prophylaxis with IFNβ-1 reduces the probability of SARS-CoV-2 transmission within a household.</p>



Interferon Beta-1 α ring prophylaxis to reduce household transmission of SARS-CoV-2

Authors

José A. Castro-Rodriguez, PhD
Pontifical Catholic University of Chile

Eleanor N. Fish PhD
University of Toronto

Tobi Kollmann PhD
Telethon Kids Institute

Carolina Iturriaga, RN
Pontifical Catholic University of Chile

Yuliya Karpievitch PhD
Telethon Kids Institute

Casey Shannon BSc
Prevention of Organ Failure (PROOF) Centre of Excellence

Virginia Chen BSc
Prevention of Organ Failure (PROOF) Centre of Excellence

Robert Balshaw PhD
Centre for Healthcare Innovation, University of Manitoba

Samuel Montgomery PhD
Telethon Kids Institute

Joseph Ho, MSc
Telethon Kids Institute

Rym Ben Othman, PhD
Telethon Kids Institute

Radhouana Aniba, PhD
Telethon Kids Institute

Francisca Gidi-Yunge, DDS
Pontifical Catholic University of Chile

Lucy Hartnell, MSc
Telethon Kids Institute

Guillermo Pérez-Mateluna, Biotech
Pontifical Catholic University of Chile

Marcela Urzúa, RN
Pontifical Catholic University of Chile

Scott Tebbutt, PhD
Prevention of Organ Failure (PROOF) Centre of Excellence

Diego García-Huidobro, PhD
Pontifical Catholic University of Chile

Cecilia Perret, MD
Pontifical Catholic University of Chile

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Arturo Borzutzky, MD
2 Pontifical Catholic University of Chile

3 Stephen M. Stick, PhD
4 Telethon Kids Institute

5
6 **Corresponding author:** Professor Stephen Stick
7 stephen.stick@health.wa.gov.au

Confidential: For Review

1
2 **1 Abstract (words 250)**

3
4 **2**
5 **3 Background**

6
7 **4** Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical
8
9 **5** determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding.
10
11 **6** Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFN β -1 α could
12
13 **7** reduce SARS-CoV-2 household transmission.

14
15
16 **8**
17 **Methods**

18
19 **9** A household cluster randomized controlled study of IFN β -1 α administered to non-hospitalized,
20
21 **10** symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years
22
23 **11** compared to standard care, was conducted. Following randomization participants received IFN β -1 α
24
25 **12** on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary
26
27 **13** polymerase chain reaction measurements until day 29 in both study arms. A post-hoc ‘at risk
28
29 **14** population’ was defined as households where the index case was positive at the start of the study and
30
31 **15** there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2.
32
33 **16** Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i)
34
35 **17** reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household
36
37 **18** contacts.
38
39
40
41
42

43
44 **19 Results**

45
46 **20** In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive
47
48 **21** IFN β -1 α and 565 to standard care. Based on intention to treat and per protocol analyses, IFN β -1 α
49
50 **22** treatment was ineffective. However, in the ‘at risk’ population, the relative risk of infection was
51
52 **23** reduced by 23% in treated individuals and that there was a 95% probability that IFN β -1 α reduced
53
54 **24** household transmission.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Conclusion

2 Ring prophylaxis with IFN β -1 α reduces the probability of SARS-CoV-2 transmission within a

3 household.

4

Confidential: For Review

1
2 **1 Introduction (Words 3284)**
3

4 2 The SARS-CoV-2 pandemic has claimed over six million lives. Despite the rapid development and
5
6 deployment of vaccines in many countries, the number of new cases worldwide still exceeds 500,000
7 3
8 daily (<https://covid19.who.int>). With each wave of the pandemic, health systems have been
9 4
10 challenged and the likelihood of emergence of mutant strains of the virus remains. Mutated strains
11 5
12 may be more transmissible ^{1,2}, cause more severe disease than the original pandemic strain of SARS-
13
14 CoV-2 ³ and have the potential to evade available vaccines ^{4,5}. Whilst widespread vaccination has had
15
16 success limiting the trajectory of the pandemic, the emergence of the omicron variants demonstrated
17 7
18 that even with mutations that appear to cause less severe disease ⁶, high transmission despite
19 8
20 immunization could still result in significant pressures on health services ⁷.
21 9
22
23
24 10

25
26
27 11
28 12 The solution to halting any pandemic is ending community transmission. During the current
29
30 pandemic, measures such as healthy hygiene, self-isolation when sick, physical-distancing and use of
31 13
32 facemasks have all been effective ⁸. Moreover, expedited public health responses such as extensive
33 14
34 contact-tracing, testing for infection and community lockdowns have all been effective methods to
35 15
36 curb transmission ⁹. International and local border closures plus strict quarantine measures have
37
38 reduced community transmission to zero for periods in countries such as Australia and New Zealand
39
40 ^{10,11}. However, in these countries and elsewhere, as restrictions are relaxed, localized outbreaks have
41 17
42 occurred ¹² that have required rapid, community-wide responses to again suppress transmission.
43 18
44
45 19 Importantly, these community constraints cause unprecedented civil disruption and come at
46
47 enormous economic ^{13,14} and social costs ^{15,16}.
48 20
49
50 21

51
52 22
53
54
55 23
56
57
58
59
60

1
2 1 Since the evolution of dominant SARS-CoV-2 virus cannot be easily predicted¹⁷, there remains a need
3
4 2 to identify interventions that can be rapidly deployed should highly pathogenic strains emerge despite
5
6
7 3 high levels of community immunization. Furthermore, preparations for the next pandemic must
8
9 4 include strategies to limit the potential for infection and transmission on first contact with pathogenic
10
11
12 5 respiratory viruses.

13
14 6
15
16 7 One of the many therapeutic approaches investigated that appeared clinically useful early in the
17
18
19 8 course of the pandemic was treatment with type 1 interferons (IFNs). Randomized, controlled studies
20
21
22 9 suggest that IFNs offer clinical benefits in moderate¹⁸ and severe disease^{19,20} }, reduce the duration
23
24 10 of viral shedding²¹ and prevent infection in front-line hospital workers²². Nonetheless, IFNs are not
25
26
27 11 generally recommended for treatment of proven cases of Covid-19²³.

28
29 12
30
31 13 Since IFNs are sentinel innate immune signalling molecules produced early after first contact with viral
32
33
34 14 pathogens²⁴⁻²⁶, we postulated that prophylactic IFN treatment might reduce susceptibility to infection
35
36 15 of uninfected contacts of individuals with SARS-CoV-2 infection. Such post-exposure prophylaxis could
37
38
39 16 provide non-specific, antiviral protection to curb episodic viral outbreaks²⁷, help suppress community
40
41 17 transmission, even in vaccinated populations, and therefore reduce the risk of emergence of
42
43
44 18 dangerous mutations^{4,28}.

45
46 19
47
48 20 We therefore undertook a cluster, randomized, controlled study of sub-cutaneous pegylated IFN β -1 α
49
50
51 21 (Plegridy. Biogen Inc, Cambridge MA) administration to determine whether IFN β -1 α therapy given to
52
53
54 22 index cases and household contacts can reduce transmission of SARS-CoV-2.
55

56 23
57
58
59
60
Confidential: Destroy when review is complete.

1 **Methods**

2 The Containing Coronavirus Disease-19 (ConCorD-19) trial was a prospective,
3 cluster, randomized trial of subcutaneous (sc) administration of pegylated IFN β -1 α (Plegridy, Biogen
4 Inc, Switzerland) versus standard care (control) ²⁹. Each household of an index case was randomized
5 to either the IFN β -1 α treatment or the standard care control arm. The study was approved by the
6 Institutional Review Board of the Pontificia Universidad Católica de Chile and was registered with
7 clinicaltrials.gov (NCT04552379). All participants provided written informed consent.

8 9 *Trial population*

10 Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19
11 clinics and emergency room visits in Santiago, Chile. Households were contacted by telephone to
12 determine eligibility prior to enrolment. Individuals aged between 18 and 80 years who met inclusion
13 and exclusion criteria were deemed as ‘eligible’ contacts with households only included if there was at
14 least one eligible contact ²⁹. Enrolment and the first doses of IFN β -1 α - if in the intervention arm- had
15 to be within 72 hours of the positive identification of SARS-CoV-2 by polymerase chain reaction (PCR)
16 in index cases. A household was excluded if the index case had been in complete self-quarantine
17 from other household members during the 48 hours prior to the diagnosis of SARS-CoV-2 infection ²⁹.
18 Household characteristics were captured consistent with recommendations of the World Health
19 Organization for assessing household transmission ³⁰. All participants implemented quarantine
20 measures as mandated by local authorities and maintained a daily symptom diary which was collected
21 and reviewed at each study visit by the study team (see online supplementary material). At any time
22 during the trial, if a contact participant developed symptoms suggestive of COVID-19, a
23 nasopharyngeal swab was taken by a member of a mobile health team for virus PCR testing in an

1
2 1 accredited SARS-CoV-2 diagnostic laboratory. Index cases were instructed to remain in isolation /
3
4 2 quarantine for 11 days from onset of symptoms or, if asymptomatic, 11 days from the
5
6
7 3 sample collection date that resulted in the COVID-19 diagnosis. Household contacts remained in
8
9 4 isolation / quarantine for 11 days from date of the sample resulting in the diagnosis of the index case
10
11
12 5 or of a newly diagnosed household member as per recommendations/rulings by local authorities.
13

14 6 15 16 7 *Intervention*

18
19 8 A mobile health team conducted home visits of all participant households on study days 1
20
21 9 (enrolment), 6, 11, 16 and 29. Index cases and eligible household contacts in the IFN β -1 α arm
22
23
24 10 received three subcutaneous doses of pegylated IFN β -1 α (125 μ g/0.5ml x 0.5ml) on study days 1, 6
25
26
27 11 and 11. Ineligible contacts in the IFN β -1 α arm, as well as index cases and all household contacts in
28
29 12 the SOC arm, received standard care. All participating households received information regarding
30
31
32 13 hygiene, isolation, social distancing and wearing of facemasks as per public health advice at the time
33
34 14 of enrolment. The IFN β -1 α injection was given by a trained member of a mobile health team and
35
36
37 15 participants were recommended to take paracetamol (1000mg, 6 hourly) commencing at the same
38
39 16 time as the IFN β -1 α for up to twenty-four hours, in order to mitigate predictable flu-like symptoms
40
41 17 ³¹.
42
43

44 18 45 46 19 *Outcomes*

47
48
49 20 The primary outcomes were (i) the proportion of index cases shedding SARS-CoV-2 at study day 11 in
50
51 21 the IFN β -1 α compared to control arm and (ii) the proportion of household contacts shedding SARS-
52
53
54 22 CoV-2 at day 11, in the IFN β -1 α compared to the control arm. Secondary and exploratory outcomes
55
56 23 are listed in Supplementary Methods (Supplementary Table 1). Shedding was determined by the
57
58
59
60

1
2 1 presence of SARS-CoV-2 by PCR in saliva collected on days 1, 6, 11, 16, 21, and 29 (see Supplementary
3
4 2 Methods). A SARS-CoV-2 PCR Ct value ≥ 40 was considered negative. Viral load was estimated from
5
6
7 3 the Ct value using a standard algorithm (Supplementary Figure 1
8
9
10 4

11 5 *Biospecimen collections*

12 6 The full schedule of biospecimen collection is provided in the supplementary methods
13
14 7 (Supplementary Tables 2 and 3. All consenting, non-eligible household contacts also provided
15
16
17 8 biospecimens according to the schedule collection for non-eligible household contacts.
18
19
20
21 9

22 10 *Adverse events*

23
24 11 These were classified in accordance with Good Clinical Practice ³², as non-serious or serious and as
25
26
27 12 related or unrelated to the trial medication.
28
29
30
31 13

32 14 *Statistical considerations*

33
34 15 The study was designed at the start of the pandemic and there were few data to guide sample size
35
36
37 16 calculations. We therefore planned both frequentist inference and Bayesian analyses based on
38
39
40
41 17 assumptions from the available data.
42
43
44 18

45
46 19 Households were randomized as individual clusters using a minimization technique (biased coin,
47
48
49 20 $P=0.7$) in order to achieve balance between treatment arms, stratified by the number of people within
50
51 21 the household ³³.
52
53 22
54
55
56
57
58
59
60

1
2 1 Sample size calculations assumed, $\alpha=0.025$ and power 90%, a zero correlation between outcome
3
4 2 measures and that the household-wise, type 1 error rate would be below 0.05 and power above 80%.
5
6
7 3 The estimated average household size was 4, based on census data ³⁴.

8
9 4
10
11
12 5 Primary outcomes:

13
14 6 (i) SARS-CoV-2 shedding at study day 11 by index cases: Data from Wuhan suggested that the
15
16 7 proportion of untreated index cases still shedding virus on study day 11 would be ~85% ³⁵. Based on a
17
18 8 two tailed Fisher's exact test, a sample size of 278 index cases (139 per arm) would have 90% power
19
20 9 to detect a difference in the proportion of individuals shedding virus at study day 11, if the proportion
21
22 10 in the IFN β -1 α arm was 65%.

23
24
25
26 11
27
28
29 12 (ii) SARS-CoV-2 shedding at study day 11 by household contacts: We estimated the secondary
30
31 13 infection rate (transmission within the household) where there is an untreated index case would
32
33 14 be 28% ^{36,37}. Based on a stratified Cochran-Mantel-Haenszel test (two-tailed with intra-class
34
35 15 correlation of 0.15), we estimated that a sample of 278 households (834 eligible household contacts)
36
37 16 would have >90% power, at alpha 0.025, to detect an odds ratio of 0.5 for a reduction in transmission
38
39 17 to a treated household contact.

40
41
42
43 18
44
45
46 19 Based on these assumptions and estimates, we aimed to recruit 310 households (allowing for a 10%
47
48 20 drop-out rate) and 930 eligible household contacts.

49
50
51 21
52
53 22 We undertook 3 separate sets of analyses:

1
2 1 (A) Standard frequentist analyses based on the primary outcomes as stated in the protocol and
3
4 2 described in the Statistical Analysis Plan (available online) and included intention to treat and per
5
6 3 protocol approaches .

7
8
9 4 (B) Exploratory frequentist analyses based on a modified dataset that accounted for biological
10
11 5 implausibility and effects that might only be associated with active treatment (Figure 1 and
12
13 6 Supplementary Table 1 for further explanations).

14
15
16 7 Both frequentist analyses fitted linear mixed effects models using lme4³⁸ (see Statistical Analysis
17
18 8 Plan).

19
20
21 9 (C) Exploratory Bayesian analyses using the same dataset as the exploratory frequentist analysis.
22
23 10 Detailed methods are provided in the supplementary methods. Briefly, a generalized linear model
24
25 11 with mixed effects was developed to estimate the probability of infection that is influenced by
26
27 12 explanatory variables for each contact case. A stan_glm with binomial logit function in rstanarm R
28
29 13 package was used^{39,40}.

30
31
32
33
34 14
35
36 15 The frequentist approach allowed us to estimate the effects of IFN β -1 α treatment on the risk of an
37
38 16 *individual* becoming infected. Whereas the Bayesian analysis allowed us to determine whether the
39
40 17 ring prophylaxis strategy using IFN β -1 α reduces the probability of transmission within the household
41
42 18 of an infected index case.

43
44
45
46 19
47
48 20 With regard to the filtered datasets, we observed, after locking the database, that a number of index
49
50 21 cases had negative PCR results on the day of recruitment despite a previous positive diagnostic PCR
51
52 22 test. In the exploratory analyses we therefore excluded households where the index case was
53
54 23 unlikely to transmit virus because they were not shedding virus on days 1 and day 6 of the study. We
55
56
57
58
59
60

1
2 1 also excluded households where an eligible contact was already positive at recruitment and there
3
4 2 were no other eligible negative cases in the household. We refer to the modified dataset as the
5
6 3 population "at risk". We used the population at risk data to better understand the effects of IFN β -1 α
7
8 4 treatment on transmission of virus within households.
9
10

11
12 5
13
14 6 When undertaking these exploratory analyses, we considered effects during two time periods. Days
15
16 7 1-11 (Period 1) i.e., the treatment and isolation period when eligible contacts in the IFN β -1 α arm
17
18 8 were likely to have elevated IFN levels based on the known pharmacokinetics of pegylated IFN β -1 α
19
20 9 and days 12-29 (Period 2) the post-treatment and isolation period when biological effects of
21
22 10 pegylated IFN β -1 α were likely to be waning in treated individuals. Although samples were not
23
24 11 obtained on days 12-15, we assumed that anyone who became infected during this period would
25
26 12 likely still to have a positive PCR on day 16.
27
28
29
30

31 13 32 33 34 14 **Results**

35
36 15 Recruitment, participation, and completion data are shown in Figure 1. Participant demographic and
37
38 16 basic household characteristics data are shown in Table 1.
39
40

41 17
42
43 18 Between December 2020 and May 2021, three-hundred and forty-one households were enrolled and
44
45 19 randomized, of which 137 (IFN β -1 α arm) and 151 (control arm) completed the study. Of the 1172
46
47 20 individuals randomized (IFN β -1 α arm = 607; Controls = 565), 53 individuals withdrew from the study,
48
49 21 of which 15 were index cases; 35 (14 index cases) in the IFN β -1 α arm and 18 (1 index case) in the
50
51 22 control arm. The reasons for withdrawal are summarized in the supplementary results
52
53 23 (Supplementary Table 4). One index case withdrew before being allocated to a treatment arm.
54
55
56
57
58
59
60

1
2 1
3
4 2 Eighty-two households where the index case had a negative salivary PCR on Day 1 and 6, or where
5
6
7 3 there were no eligible contacts who tested negative at recruitment, were excluded from the
8
9 4 exploratory analyses. The remaining households were considered as the 'at risk' population. (Figure
10
11
12 5 1).

13
14 6
15
16 7 *(a) Primary analyses*

17
18
19 8 The outcomes for the intention to treat (ITT) and per protocol (PP) frequentist analyses were similar
20
21 9 (Supplementary Results). There was no effect of IFN β -1 α treatment on duration of viral shedding in
22
23
24 10 those treated (index cases or infected contacts) vs. controls (IC-INF: treatment OR = 0.979, 95%CI =
25
26 11 0.647 to 1.479); IC-ITT: treatment OR = 1.106, 95%CI = 0.657 to 1.863); IC-PP: treatment OR = 1.062,
27
28
29 12 95%CI = 0.622 to 1.810); Figure 2A). The observed reduction in transmission to household contacts
30
31 13 associated with IFN β -1 α by day 11 was not significant (EHC-ITT: treatment OR = 0.582, 95%CI
32
33
34 14 = 0.271 to 1.247; HC: treatment OR = 0.577, 95%CI = 0.287 to 1.160; EHC-PP: treatment OR = 0.589,
35
36 15 95%CI = 0.272 to 1.276; Figure 2B). Vaccination status did not affect these outcomes (Supplementary
37
38
39 16 results).

40
41 17 *(b) Exploratory frequentist analysis of 'At Risk Population.'*

42
43 18 Of the at risk population, 33/164 (20%) in the IFN β -1 α arm became infected by day 29 of the study
44
45
46 19 compared to 37/142 (26%) in the control arm (relative risk reduction in the IFN arm = 23%). The
47
48
49 20 majority of the risk reduction occurred during the active treatment phase of the study (days 1 to 11).
50
51 21 Treatment with IFN β -1 α was associated with a significant reduction in the odds of a positive saliva
52
53 22 PCR for all household contacts compared to standard of care on Day 11 (p = 0.033; OR = 0.550, 95% CI
54
55
56
57
58
59
60

1
2 1 = 0.364 to 0.989). The treatment effect was not significant in the second period (days 12-29) was
3
4 2 not significant (OR = 0.968, 95% CI = 0.405 to 2.840) (Figure 2C)
5
6

7 3
8
9 4 *(c) Exploratory Bayesian analysis:*
10

11 5 Overall, there was a 95% probability of infection reduction within a household by IFN β -1 α treatment
12 6 and the credible interval for the reduction in transmission probability was in the order of 0.9 to
13
14 7 15.9%. During the active treatment period (days 1-11), there was a significant reduction in the odds of
15
16 8 transmission (Bayesian analysis (OR = 0.32, 95% Credible Interval = 0.11 to 0.83). In contrast, in
17 9 Period 2 (day 12-29), the 95% credible interval of *Beta* coefficients for the treatment group includes
18
19 10 zero and therefore treatment was not effective in this period (Figure 2C, Supplementary Figure 2).
20
21
22
23

24 11 The effect of IFN β -1 α on transmission was independent of household size (Supplementary Figure 3)
25
26
27
28
29 12

30
31 13 To determine the effect of IFN β -1 α treatment on viral shedding in those who became infected, we
32 14 examined the viral load trajectories in household contacts who became PCR positive after day 1. We
33
34 15 did not observe any difference in viral load trajectory in those treated with IFN β -1 α compared to
35
36 16 controls (Figure 3A). Furthermore, there was no difference in peak viral load between treated
37
38 17 household contacts and controls who became infected (Figure 3B).
39
40
41
42
43
44 18

45
46 19 There were fifty-eight serious adverse events in index cases, twenty-seven hospitalizations due to
47
48 20 COVID-19 (25 in the treatment and 32 in the control arm) and was one death in the standard care arm
49
50
51 21 due to COVID-19 in an individual with significant co-morbidities. Twenty-six household contacts of
52
53 22 index cases were hospitalized, 10 in the treatment arm and 16 in the control arm, the difference was
54
55
56 23 not statistically significant.
57
58
59
60

1
2 1
3
4 2 **Discussion**

5
6
7 3 This prospective, household cluster randomized, ring prophylaxis trial demonstrated that pegylated
8
9 4 IFN β -1 α may reduce household transmission of SARS-CoV-19. Pegylated IFN β -1 α is an FDA
10
11 5 approved therapy for hepatitis C and multiple sclerosis for which the pharmacokinetics and safety
12
13 6 profile are well-characterized ⁴¹. The use of this formulation allowed us to predict the likely duration
14
15 7 of activity of the three-dose regimen in order to cover the period of peak transmissibility of the virus.
16
17 8 Using a mobile medical team to administer doses at home optimized adherence to therapy and
18
19 9 allowed reasons for non-adherence and withdrawal to be accurately documented.
20
21
22
23

24 10
25
26 11 Although the intention to treat and per protocol analyses failed to demonstrate a significant effect on
27
28 12 primary outcomes, these analyses failed to account for index cases not shedding virus at
29
30 13 randomization nor an absence of eligible contacts within a household. Using biologically plausible
31
32 14 filters to define an at-risk population provided a better understanding of the effects of IFN β -1 α than
33
34 15 intention to treat or per protocol analyses. These exploratory analyses that took account of the
35
36 16 likelihood that transmission could occur within a household provided a pragmatic assessment of the
37
38 17 effects of IFN β -1 α therapy when given to household contacts as prophylaxis.
39
40
41
42
43
44 18

45
46 19 The frequentist analysis of the at-risk populations indicated that *individuals* treated with IFN were less
47
48 20 likely to become infected than untreated individuals when exposed to virus with a relative risk
49
50 21 reduction of 23%. The Bayesian analysis revealed that the probability was 95% that transmission was
51
52 22 reduced in *households* randomized to IFN β -1 α therapy. This effect of IFN β -1 α on household
53
54 23 transmission was only significant during the active treatment period. This highlights the physiological
55
56
57
58
59
60

1
2 1 importance of IFN β -1 α as a sentinel molecule²⁴ and provides further evidence for post-exposure
3
4 2 prophylaxis with IFN β -1 α as an antiviral strategy.
5
6

7 3
8
9 4 To our knowledge, only one previous study assessed ring prophylaxis in COVID-19. Labhardt et al
10
11 5 observed that a combination of lopinavir/ritonavir for 5 days as post-exposure prophylaxis was not
12
13 6 effective at preventing infection in close contacts of index cases⁴².
14
15
16

17 7
18
19 8 The overall viral load trajectory we observed was very similar to that observed in a laboratory human
20
21 9 challenge experiment using wild-type SARS-CoV-2 virus in healthy volunteers⁴³. Treatment with
22
23 10 IFN β -1 α had no effect on viral load trajectory; therefore, reduced viral shedding by infected
24
25 11 individuals is unlikely to explain the protective effect on household transmission of IFN β -1 α treatment
26
27 12 that we report. Given that treatment affected the probability of transmission only in the active
28
29 13 treatment phase and appears unrelated to viral load, we speculate that the observed effects of IFN β -
30
31 14 1 α were direct through protection of the at-risk, exposed individual rather than indirectly through
32
33 15 effects on the index case. The ConCoRD-19 biorepository will allow further examination of the
34
35 16 mechanisms of action of IFN β -1 α on resistance to infection.
36
37
38

39 17
40
41 18 The study was undertaken prior to the emergence of the omicron strain of virus. We calculated the
42
43 19 sample size based upon known household transmission characteristics of the alpha strain which was
44
45 20 the dominant strain of the virus early in the pandemic. Simple hygiene measures and quarantine of
46
47 21 affected individuals within households could have contributed to lower rates of transmission than
48
49 22 expected. Together with a smaller number of eligible household contacts than anticipated from
50
51 23 census data, these factors may have reduced the power of the study for the primary outcomes. The
52
53
54
55
56
57
58
59
60

1
2 1 effect size observed in this study could be greater for variants with higher transmissibility such as the
3
4 2 Omicron strains that are now the dominant worldwide.
5
6
7 3 Nonetheless, the beneficial biological effect of IFN β -1 α treatment was evident in the at-risk
8
9 4 population and therefore, post-exposure or ring prophylaxis with IFN β -1 α warrants further
10
11 5 investigation, particularly if additional virulent strains of SARS-CoV-2 emerge and for future pandemic
12
13 6 virus preparedness.
14
15
16
17 7

18
19 8 In summary, although intention to treat and per protocol analyses failed to demonstrate significant
20
21 9 effects on primary outcomes, in a biologically defined, at risk population, the relative risk of infection
22
23 10 for an individual treated with pegylated IFN β -1 α was reduced by 23.0%. Moreover, this is the first
24
25 11 study to demonstrate ring prophylaxis with pegylated IFN β -1 α significantly reduces the probability of
26
27 12 household transmission of SARS-CoV-2. The effect of pegylated IFN β -1 α was most obvious during the
28
29 13 active phase of treatment. In situations where there is emergence of a highly pathogenic and
30
31 14 transmissible mutant strain of SARS-CoV-2 despite high vaccination rates, or when there is a new viral
32
33 15 pandemic, IFN β -1 α ring prophylaxis could be considered to reduce transmission in households or
34
35 16 amongst critical workers and vulnerable communities. Ring prophylaxis with therapies that can
36
37 17 interrupt transmission appears to be an effective strategy for highly contagious respiratory viruses.
38
39
40
41
42
43
44 18

46 19 **Funding.**

47 20 Biogen PTY Ltd. Supply of interferon as "Plegridy".
48 21 The study was substantially funded by BHP Holdings Pty Ltd
49 22

51 23 **Authorship**

52 24 Authors, Castro-Rodriguez; Fish; Kollmann; Iturriaga, Karpievitch and Shannon contributed equally to
53 25 the conduct of the study and manuscript as first authors.
54 26

55 26
56 27 Authors, Tebbutt, Diego García-Huidobro, Perret, Borzutsky and Stick contributed equally to the
57 28 conduct of the study and manuscript as senior authors.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

Matthew Cooper (Telethon Kids Institute). Advice regarding protocol and establishment of randomization schedule.

Alexia Foti (Telethon Kids Institute). Collating, reviewing, and editing documents.

Zsuzsanna Hollander (PROOF Centre, Vancouver). Statistical advice and statistical analysis plan review.

Nat Eiffler (Telethon Kids Institute). Project management, protocol development, data management.

Jessica Meyer (University of Rochester). Assisting collation and formatting of tables and figures.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

- 1
2 1 10. National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 38
3
4 2 Reporting period ending 28 March 2021. *Commun Dis Intell* (2018) 2021;45. DOI:
5
6 3 10.33321/cdi.2021.45.19.
7
8
9 4 11. Houvessou GM, Souza TP, Silveira MFD. Lockdown-type containment measures for COVID-19
10
11 prevention and control: a descriptive ecological study with data from South Africa, Germany, Brazil,
12 5
13 Spain, United States, Italy and New Zealand, February - August 2020. *Epidemiol Serv Saude*
14 6
15 2021;30(1):e2020513. DOI: 10.1590/S1679-49742021000100025.
16 7
17
18 12. Conway SR, Lazarski CA, Field NE, et al. SARS-CoV-2-Specific T Cell Responses Are Stronger in
19 8
20 Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-
21 9
22 CoV-2 Infection. *Front Immunol* 2021;12:793197. DOI: 10.3389/fimmu.2021.793197.
23
24 10
25
26 11 13. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *JAMA*
27
28 2020;324(15):1495-1496. DOI: 10.1001/jama.2020.19759.
29 12
30
31 13 14. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand
32
33 out in high-frequency shipping data. *PLoS One* 2021;16(4):e0248818. DOI:
34 14
35 10.1371/journal.pone.0248818.
36 15
37
38 15. Chemen S, Gopalla YN. Lived experiences of older adults living in the community during the
39 16
40 COVID-19 lockdown - The case of mauritius. *J Aging Stud* 2021;57:100932. DOI:
41 17
42 10.1016/j.jaging.2021.100932.
43 18
44
45 16. Mamun MA. Suicide and Suicidal Behaviors in the Context of COVID-19 Pandemic in Bangladesh:
46 19
47 A Systematic Review. *Psychol Res Behav Manag* 2021;14:695-704. DOI: 10.2147/PRBM.S315760.
48 20
49
50 17. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. *Nature* 2021;600(7888):204-
51 21
52 207. DOI: 10.1038/d41586-021-03619-8.
53 22
54
55
56
57
58
59
60

1
2 1 18. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β -1b in treatment of severe COVID-
3
4 2 19: A randomized clinical trial. *Int Immunopharmacol* 2020;88:106903. (In eng). DOI:
5
6 3 10.1016/j.intimp.2020.106903.
7
8 4 19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe
9
10 5 COVID-19: the COVIFERON randomized controlled trial. *Sci Rep* 2021;11(1):8059. (In eng). DOI:
11
12 6 10.1038/s41598-021-86859-y.
13
14 7 20. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and
15
16 8 Safety of Interferon β -1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother* 2020;64(9)
17
18 9 (In eng). DOI: 10.1128/aac.01061-20.
19
20 10 21. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with
21
22 11 COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021;9(5):498-510. (In
23
24 12 eng). DOI: 10.1016/s2213-2600(20)30566-x.
25
26 13 22. Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to
27
28 14 Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. *Curr Top Med Chem*
29
30 15 2021;21(10):920-927. (In eng). DOI: 10.2174/1568026621666210429083050.
31
32 16 23. National Institutes of Health. Covid-19 Treatment Guidelines. In: Health NIH, ed.: United States
33
34 17 Government; 2021.
35
36 18 24. Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. *Front Immunol* 2018;9:2061.
37
38 19 DOI: 10.3389/fimmu.2018.02061.
39
40 20 25. Mazewski C, Perez RE, Fish EN, Plataniias LC. Type I Interferon (IFN)-Regulated Activation of
41
42 21 Canonical and Non-Canonical Signaling Pathways. *Front Immunol* 2020;11:606456. DOI:
43
44 22 10.3389/fimmu.2020.606456.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 1 26. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. *Semin Immunol*
3
4 2 2019;43:101300. DOI: 10.1016/j.smim.2019.101300.
5
6
7 3 27. World Health Organization. Informal consultation on the role of therapeutics in COVID-19
8
9 4 prophylaxis and post-exposure prophylaxis. . Worl Health Organization.
10
11
12 5 28. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? *Int J*
13
14 6 *Environ Res Public Health* 2020;17(11):3997. (In eng). DOI: 10.3390/ijerph17113997.
15
16
17 7 29. Iturriaga C, Eiffler N, Aniba R, et al. A cluster randomized trial of interferon ss-1a for the reduction
18
19 8 of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).
20
21 9 *BMC Infect Dis* 2021;21(1):814. DOI: 10.1186/s12879-021-06519-4.
22
23
24 10 30. World Health Organization. Household transmission investigation protocol for 2019-novel
25
26 11 coronavirus (COVID-19) infection. Epidemiological protocol. Geneva: World Health Organization,
27
28 February 28th 2020 2020. (WHO/2019-nCoV/HHtransmission/2020.4)
29 12
30
31 13 ([https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)
32
33 [novel-coronavirus-\(2019-ncov\)-infection](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)).
34 14
35
36 15 31. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally
37
38 16 effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during
39
40 17 interferon beta-1a (AVONEX) therapy. *Mult Scler* 2002;8(1):15-8. DOI: 10.1191/1352458502ms771sr.
41
42
43 18 32. National Health and Medical Research Council. Guidance: Safety monitoring and reporting in
44
45 19 clinical trials involving therapeutic goods. Canberra: National Health and Medical Research Council;
46
47 20 2016.
48
49
50
51 21 33. Hofmeijer J, Anema PC, van der Tweel I. New algorithm for treatment allocation reduced
52
53 22 selection bias and loss of power in small trials. *J Clin Epidemiol* 2008;61(2):119-24. DOI:
54
55 23 10.1016/j.jclinepi.2007.04.002.
56
57
58
59
60

- 1 34. National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile:
2
3
4 2 National Institute of Statistics (Chile), 2021. ([http://ghdx.healthdata.org/record/chile-population-and-](http://ghdx.healthdata.org/record/chile-population-and-housing-census-2017)
5
6
7 3 [housing-census-2017](http://ghdx.healthdata.org/record/chile-population-and-housing-census-2017)).
- 8
9 4 35. World Health Organisation. Situation report - 50. Coronavirus disease 2019 (COVID-19) 50. World
10
11
12 5 Health Organisation, 2020. ([https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
13
14 6 [2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)).
- 15
16 7 36. Yi B, Fen G, Cao D, et al. Epidemiological and clinical characteristics of 214 families with COVID-19
17
18
19 8 in Wuhan, China. Int J Infect Dis 2021. DOI: 10.1016/j.ijid.2021.02.021.
- 20
21 9 37. Curmei M, Ilyas A, Evans O, Steinhardt J. Constructing and adjusting estimates for household
22
23
24 10 transmission of SARS-CoV-2 from prior studies, widespread-testing and contact-tracing data. Int J
25
26 11 Epidemiol 2021;50(5):1444-1457. DOI: 10.1093/ije/dyab108.
- 27
28
29 12 38. Bates DM, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using lme4. Journal of
30
31 13 Statistical Software 2015;67(1):1-48. DOI: doi:10.18637/jss.v067.i01.
- 32
33
34 14 39. Goodrich B, Gabry J, Ali I, S. B. Bayesian applied regression modeling via Stan. R package version
35
36 15 2.21.1. rstanarm 2020 (<https://mc-stan.org/rstanarm>).
- 37
38
39 16 40. Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Wolfe R. Joint longitudinal and
40
41 17 time-to-event models via Stan. StanCon 2018. 10-12 Jan 2018. Pacific Grove C, USA.
42
43 18 https://github.com/stan-dev/stancon_talks/. Joint longitudinal and time-to-event models via Stan. .
44
45 19 StanCon 2018. Pacific Grove, CA, USA2018.
- 46
47
48 20 41. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of
49
50
51 21 peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol
52
53 22 2015;55(2):179-88. DOI: 10.1002/jcph.390.
- 54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 42. Labhardt ND, Smit M, Petignat I, et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus
2 Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster
3 Randomized Trial. *EClinicalMedicine* 2021;42:101188. DOI: 10.1016/j.eclinm.2021.101188.
4 43. Ben K, Alex M, Mariya K, et al. *Nature Portfolio* 2022. DOI: 10.21203/rs.3.rs-1121993/v1.

Confidential: For Review

	Full study population		At-risk population	
	SOC (n = 565)	IFN (n = 607)	SOC (n = 246)	IFN (n = 293)
Age (years)				
Mean (SD)	35.0 (19.4)	33.2 (18.7)	29.2 (21.0)	29.0 (20.0)
Sex				
Female, n (%)	294 (52.0%)	323 (53.2%)	133 (54.1%)	171 (58.4%)
Male, n (%)	271 (48.0%)	284 (46.8%)	113 (45.9%)	122 (41.6%)
Household occupants				
Mean (SD)	4.10 (1.31)		4.28 (1.30)	4.86 (2.24)
Fully vaccinated for SARS-CoV-2				
No, n (%)	380 (67.3%)	438 (72.2%)	167 (67.9%)	217 (74.1%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Yes, n (%)	103 (20.3%)	169 (27.8%)	79 (32.1%)	76 (25.9%)
Cancer				
No, n (%)	559 (98.9%)	598 (98.5%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	5 (0.9%)	9 (1.5%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Diabetes				
No, n (%)	542 (95.9%)	583 (96.0%)	238 (96.7%)	285 (97.3%)
Yes, n (%)	22 (3.9%)	24 (4.0%)	7 (2.8%)	8 (2.7%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Heart disease				
No, n (%)	533 (94.3%)	578 (95.2%)	236 (95.9%)	281 (95.9%)
Yes, n (%)	31 (5.5%)	29 (4.8%)	9 (3.7%)	12 (4.1%)

Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Asthma				
No, n (%)	524 (92.7%)	581 (95.7%)	230 (93.5%)	282 (96.2%)
Yes, n (%)	40 (7.1%)	26 (4.3%)	15 (6.1%)	11 (3.8%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic lung disease				
No, n (%)	564 (99.8%)	606 (99.8%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	1 (0.2%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Chronic kidney disease				
No, n (%)	564 (99.8%)	604 (99.5%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	3 (0.5%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronic neurological disease				
No, n (%)	562 (99.5%)	602 (99.2%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	2 (0.4%)	5 (0.8%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
Smoker				
No, n (%)	502 (88.8%)	519 (85.5%)	227 (92.3%)	255 (87.0%)
Yes, n (%)	63 (11.2%)	88 (14.5%)	19 (7.7%)	38 (13.0%)
Missing, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

1 **Table 1: Full study population demographics at baseline, and at-risk population demographics**
2 **at baseline.**





Figure 1: CONSORT diagram describing participant screening, enrolment, randomisation, and analysis.

Confidential: Destroy when review is complete.

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.




1 **Figure 2: Forrest plots describing primary and exploratory study outcomes. (A)** odds ratios
 2 for index case populations in Primary Analysis 1 and associated sensitivity analyses, to
 3 compare the probability of being SARS-COV-2 negative vs positive on study day 11 in
 4 either treatment or standard of care arms. **(B)** odds ratios for household contact
 5 populations in Primary Analysis 2 and associated sensitivity analyses, to compare the
 6 probability of household contacts being SARS-CoV-2 negative vs positive on study day 11

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 in either treatment or standard of care arms (IC) odds ratios for the exploratory frequentist
2
3
4
5
6 and Bayesian analysis, to determine if IFN is associated with a reduction in the number of
7
8
9 positive COVID-19 tests in household contacts across study period 1 (days 1-11) and
10
11
12 study period 2 (days 12-29). Treatment with IFN is associated with a significant reduction
13
14
15 in the odds of a positive COVID-19 test for all household contacts compared to standard of
16
17
18 care; frequentist analysis ($p = 0.033$; OR = 0.550, 95% CI = 0.364 to 0.989), Bayesian
19
20
21 analysis (OR = 0.32, 95% CrI = 0.11 to 0.83). IC-INF = Infected case population (main
22
23
24 analysis), IC-ITT = Index case – intention to treat population (sensitivity analysis 7.1.3.2),
25
26
27 IC-PP = Index case – per protocol population (sensitivity analysis 7.1.3.3). EHC-ITT =
28
29
30 Treatment-eligible household contact – intention to treat population (main analysis), HC =
31
32
33 Household contact (eligible + non-eligible contacts) population (sensitivity analysis
34
35
36 7.2.3.2), EHC-PP = Treatment-eligible household contact = per protocol population
37
38
39
40
41
42
43
44 (sensitivity analysis 7.2.3.3). * $p < 0.05$.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



1 **Figure 3: Log₁₀ viral load in study participants who test positive for COVID-19 after visit 1.**

2 **(A)** No significant difference in median viral load at each study visit between SOC and IFN

3 arms. **(B)** No significant difference in peak viral load between SOC and IFN arms. SOC =

4 standard of care arm, IFN = interferon arm, cp/mL = copies/mL. n = 57 (IFN) & n = 61

5 (SOC) participants per group.

Interferon Beta-1 α ring prophylaxis to reduce household transmission of SARS-CoV-2

Supplementary Materials

Table of Contents

List of Study Investigators	4
Supplementary Methods	8
Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2.....	8
Viral load calculation.....	8
Populations used for analyses.....	9
Bayesian statistical analysis.....	9
Bayesian model.....	10
Computation of difference in probability of infection in IFN vs SOC arms	10
Supplementary Results.....	12
Bayesian analysis of infection reduction	12
Supplementary Figures	13
Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load	13
Supplementary Figure 2 Distribution of the difference in probability of infection between SOC and IFN arms by household size	14
Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms	14
Supplementary Tables.....	15
Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial.....	17
Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.....	18

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts	19
Supplementary Table 4: Study withdrawal reasons by treatment arm.	20
Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.	21
Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis.	23
Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.....	24
Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size.....	24
Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size.....	25
Supplementary Table 10: Number of contacts at each household size.	26
Supplementary References.....	27
Supplementary Appendices.....	28

List of Study Investigators

Jose A. Castro-Rodriguez

Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile,
Santiago, Chile

Eleanor N. Fish

Department of Immunology, University of Toronto, Toronto, Canada

Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

Tobias Kollman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Carolina Iturriaga

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia
Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad
Católica de Chile, Santiago, Chile

Yuliya Karpievitch

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,
Nedlands, Australia

School of Biomedical Sciences, University of Western Australia, Nedlands, Australia

Casey Shannon

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Robert Balshaw

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Virginia Chen

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Samuel T. Montgomery

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,

Nedlands, Australia

School of Population Health, Curtin University, Bentley, Australia

Joseph Ho

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,

Nedlands, Australia

Rad Aniba

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Rym Ben Othman

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Francisca Gidi-Yunge

School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Lucy Hartnell

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

Guillermo Pérez-Mateluna

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia
Universidad Católica De Chile, Santiago, Chile

Marcela Urzúa

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia
Universidad Católica De Chile, Santiago, Chile

Scott Tebbit

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

Diego García-Huidobro

Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile,
Santiago, Chile

Department of Family Medicine and Community Health, University of Minnesota, United States of
America

Cecilia Perret

Department of Pediatric Infectious Diseases and Immunology , School of Medicine, Pontificia
Universidad Católica de Chile, Santiago, Chile

Arturo Borzutzky

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia
Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad
Católica de Chile, Santiago, Chile

Stephen M. Stick

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,
Nedlands, Australia

Perth Children's Hospital, Nedlands, Australia

Supplementary Methods

Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2

RNA extraction and RT-qPCR for SARS-CoV-2 detection was performed at the Infectiology and Molecular Virology Laboratory, Red Salud UC Christus, Santiago, Chile. RNA was extracted in parallel from saliva using the MagBind RNA extraction kit (#GN7101907, Maccura Biotechnology, Rockville, MD, USA) with the Auto-Pure 32A Nucleic Purification System (Maccura Biotechnology, Rockville, MD, USA), and using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Real-time PCR amplification was performed using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) targeting the RNA-dependent RNA polymerase (RdRP) gene, targeting SARS-CoV-2, but not other SARS-like viruses (CoVNL63, CoV229E, HKE, OC43, MERS), with a positive control containing three separate diagnostic targets (E gene, N gene, RdRP). The reverse transcription and PCR processes occur in a single step in a real-time thermocycler (Lightcycler 480 II, Roche, Berlin, DE) with an analytical sensitivity of 10.6 copies per reaction. A cycle threshold (Ct) value of ≤ 37 was considered positive for SARS-CoV-2.

Viral load calculation

The viral load of SARS-CoV-2 detected in saliva was calculated using a standard curve. A commercial SARS-CoV-2 standard (#COV019, Exact Diagnostics, Fort Worth, TX, USA) at a concentration of 200,000 copies per mL (cp/mL) was extracted in triplicate using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Following extraction, serial dilutions (1:10; 200,000cp/mL to 20cp/mL & 1:5; 200,000cp/mL to 64cp/mL) were used in triplicate for reverse transcription and RT-qPCR using the LightMix Modular Wuhan CoV

RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) with the Lightcycler 480 II thermocycler (Roche, Berlin, DE), resulting in 9 replicates at each concentration. SARS-CoV-2 was detectable in all nine replicates at 200,000cp/mL, 40,000cp/mL, 20,000cp/mL, 8,000cp/mL, 2000cp/mL, and 1,600cp/mL, and a standard curve was generated using the mean Ct values for these concentrations (Supplementary Figure 1) to calculate SARS-CoV-2 viral load in samples of unknown titre, resulting in a lower limit of quantification of 1,600cp/mL.

Populations used for analyses

Participants were excluded for analysis as outlined in the statistical analysis plan, or as outlined in the exploratory analysis (Supplementary Appendix B). Total households and participants excluded and used in each population are described in Supplementary Table 6. Briefly, participants were excluded from the populations used in the primary analyses (IC-INF, IC-ITT, EHC-ITT, HC) if the study visit was not performed, or was performed outside the ± 1 day window either side of the scheduled visit date (Statistical Analysis Plan 6.5). Participants who didn't complete the full course of the treatment were excluded from the Per Protocol populations used in the primary analyses (IC-PP, EHC-PP). In the exploratory analysis, whole households were excluded if the index case was SARS-CoV-2 negative via salivary PCR at study days 1 & 6, and if there were no SARS-CoV-2 negative eligible or ineligible contacts in the household at study day 1. Participants were then excluded from the exploratory analysis if they were SARS-CoV-2 positive via salivary PCR at study day 1. Participants were further excluded from the Bayesian analysis where household size was greater than 7, as these household sizes were unable to be modelled using Bayesian modelling.

Bayesian statistical analysis

Bayesian analysis was included in the original statistical analysis plan. The goal was to test the null hypothesis that treatment of household contacts with IFN β -1 α does not reduce the probability of transmission from an infected index case to household contacts. As outlined in the analysis plan, we

used data to develop a data generating process governed by probabilities that a household contact of an index case would test positive to COVID-19, and non-informative prior was used.

Bayesian model

A generalized linear model with mixed effects was developed to estimate the probability of infection for each contact. A `stan_glm` with binomial logit function from the `rstanarm` package (1) was run using R (version 4.1.1) to obtain Beta coefficients for 4,000 simulated samples to estimate the probability of infection using the following model:

$$p_{cr} \sim (1 | index) + vacc + viral + infected + eligible + sex + age + arm$$

where: *p_{cr}*: binary COVID-19 test result, *index*: index case in the household – treated as a random effect, *vacc*: number of vaccinated household members, *viral*: log₁₀ viral load of the index case at the beginning of the period, *infected*: number of COVID-19 positive household members at the beginning of the period, *eligible*: whether the household contact was eligible for treatment, *sex*: sex of the household contact, *age*: age of the household contact, and *arm*: study arm (i.e. SOC/IFN) of the household were the fixed explanatory variables.

The features of the model were the same as the exploratory frequentist analysis, with the exception of adding the treatment period as a feature. Instead, the Bayesian analysis split the data into two periods (Period 1: study days 1–11, Period 2: study days 12–29) with analysis conducted separately. For period 2, COVID-19 positivity at day 11 was used to determine COVID-19 positive household members at the beginning of the period. The population used for analysis was the same as the “At-risk” population used in the exploratory frequentist analysis (Supplementary Table 6), with the additional exclusion of participants in households with a size larger than 8.

Computation of difference in probability of infection in IFN vs SOC arms

In each simulation, we obtained a PCR outcome for each contact from the Bayesian model by applying the `posterior_predict` function in the `rstanarm` package to the observed data (1). We further computed the percent of infections in each treatment arm irrespective of household size (Supplementary Table 8) and for each household size (Supplementary Table 9). Furthermore, we computed the difference in probability of infection by subtracting the probability of infection in IFN arm from the probability of infection in SOC arm. As a results, we obtained 4000 differences (irrespective of household size) and 4000 differences for each household size

Significance of the treatment effect was determined by 95% credible interval (CrI) for the treatment Beta coefficient. If 0 was included in the CrI, the effect of treatment group was considered not significant. Average Beta coefficient and odds ratio for the effect of the IFN treatment as compared to SOC were computed in each study period. The average odds ratio of being infected with SARS-CoV-2 on IFN treatment vs. SOC was calculated by exponentiating the values of the average of the coefficients (Supplementary Table 7).

Supplementary Results

Bayesian analysis of infection reduction


Treatment with IFN had a significant effect in study period 1 as the 95% CrI for treatment coefficient did not include zero (Supplementary Table 7). However, IFN treatment did not have a significant effect in period 2 as the 95% CrI did include zero (Supplementary Table 7).

In study period 1, there was 95% probability of infection reduction between 0.9% to 15.9% due to the IFN treatment, with 8.5% median and mean infection reduction (Supplementary Table 8). In study period 2, there are 95% probability of infection reduction -6.7% to 4.8% due to the IFN treatment, with -9% of median and mean of infection reduction (Supplementary Table 8).


When we stratified the infection reduction by household size, only households' size 3 and 4 in period 1 had a 95% CrI without zero (Supplementary Table 9).

As the distribution of Bayesian estimated differences in probabilities of infection in study period 1 is centred to the right of 0 (Supplementary Figure 3A), IFN treatment had an effect on reducing SARS-CoV-2 transmission within households. However, as the distribution in study period 2 is centred around 0, it suggests IFN has no effect on SARS-CoV-2 transmission within households (Supplementary Figure 3B).


Supplementary Figures



Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load. Mean cycle threshold (Ct) values are plotted on the y-axis, and log₁₀ SARS-CoV-2 copies per mL (cp/mL) are plotted on the x-axis. Linear regression resulted in an R² value of 0.9972, to fit the equation $y = -3.719x + 48.83$.



Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms. (A) Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical black line represents zero difference in probability of infection between SOC and IFN arms.



Supplementary Figure 3 Distribution of the difference in probability of infection between SOC and IFN arms by household size. (A) Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical dashed black line represents zero difference in probability of infection between SOC and IFN arms.

Supplementary Tables

Primary Objectives	Outcome & Outcome Measure
To determine whether IFN β -1 α treatment reduces the proportion of infected cases shedding SARS-CoV-2 at day 11 after randomization.	The proportion of index cases shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
To determine whether IFN β -1 α treatment reduces the incidence of SARS-CoV-2 transmission from index cases to treatment-eligible household contacts, as measured by any positive upper airway infection evidenced by real-time Polymerase Chain Reaction (RT-PCR), in contacts at day 11 after randomization.	The proportion of household contacts shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
Secondary Objectives	Outcome & Outcome Measure
To determine whether in index cases infected with SARS-CoV-2, IFN β -1 α treatment compared with standard of care reduces the duration of SARS-CoV-2 upper airway virus shedding over 28 days following randomization.	Duration (in days) of SARS-CoV-2 measured by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29

<p>To determine whether IFN β-1α treatment affects the incidence of SARS-CoV-2 upper airway infection or serological conversion by study day 29 in household contacts.</p>	<p>Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 & 11, and seroconversion (IgM) over the study period up to day 29</p>
<p>To determine whether IFN β-1α treatment compared with standard of care reduces the proportion of infected cases that require hospital admission or die due to COVID-19</p>	<p>The proportion of infected cases in the active arm that are hospitalized or die due to COVID-19, as compared to the proportion in the standard of care arm</p>
<p>To determine the safety of IFN β-1α in the treatment and prevention of SARS-CoV-2 infection</p>	<p>Incidence and severity of reported adverse events in the active arm compared to the standard of care arm</p>

Exploratory Objectives

Biological samples and associated data will be stored for later access for ethically approved research relevant to the exploratory objectives

- Assess the impact of participant demographic and clinical metadata on the viral transmission dynamics and response to IFN β -1 α in the household using unbiased systems epidemiology
- Assess the impact of host biology on the viral transmission dynamics and response to IFN β -1 α in the household using unbiased systems biology
- Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β -1 α intervention

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN β -1 α intervention

Estimate the secondary infection rate, serial interval, incubation period, duration of infectiousness, duration of detected shedding

Individual level: SARS-CoV-2 shedding as determined by PCR of upper respiratory samples analyzed as a function of time of exposure relative to the start of the intervention

Household/Community level: While each study arm will be assessed independently of each other as secondary objectives, we will assess the impact of any intervention on the entire household. When demographic and/or biological variables

Host immune response (anti SARS-CoV-2 antibodies, blood cytokines and chemokines), as well as blood and nasal mucosal host response (including but not limited to transcriptomics, metabolomics, proteomics, and epigenomics) to IFN β -1 α intervention, SARS-CoV-2 infection and their interaction

Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit – Suspected COVID-19
Study Day	1 Dose 1	6 Dose 2	11 Dose 3	16	21	29	
Blood Samples							
Complete Blood count/ ESR	X					X	X
SARS-CoV-2 antibodies (IgGAM)	X					X	
Study sample 1	X	X	X			X	X
Study sample 2	X	X	X			X	X
Study sample 3	X	X	X			X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples							
Saliva	X	X	X	X	X	X	X

Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.

	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Extra Visit – Suspected COVID-19
Study Day	1 Dose 1	6 Dose 2	11 Dose 3	16	21	29	
Blood Samples							
Complete Blood count/ ESR							X
SARS-CoV-2 antibodies (IgGAM)						X	
Study sample 1						X	X
Study sample 2						X	X
Study sample 3						X	X
Airway samples							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
Saliva Samples							
Saliva	X	X	X	X	X	X	X

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.

Interferon arm										Standard of Care arm									
Withdrawal reason	Days since enrolment									Withdrawal reason	Days since enrolment								
	3	4	5	10	11	14	15	21	28		3	4	5	10	11	14	15	25	28
Family withdrew	0	0	5	0	0	2	0	0	0	Family withdrew	0	0	2	0	0	0	0	0	0
Interpersonal problems	0	0	3	0	0	0	0	0	0	Interpersonal problems	0	4	0	0	0	0	0	0	0
Lack of time	0	1	0	0	0	0	0	0	0	Lack of time	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	Other	0	0	1	0	0	0	0	0	0
Parental decision	0	0	2	0	0	0	0	0	0	Parental decision	0	0	0	0	0	0	0	0	0
Poor health	0	0	1	0	0	1	0	0	0	Poor health	0	0	0	0	0	0	0	0	0
Sample collection problems	0	0	0	0	0	0	0	0	0	Sample collection problems	0	0	1	0	0	0	0	0	0
Side effects of drug	0	0	0	0	0	2	0	0	0	Side effects of drug	0	0	0	0	0	0	0	0	0
Uninterested	0	0	0	1	0	0	0	0	1	Uninterested	0	0	0	0	0	0	0	0	0
Unspecified	4	3	1	2	1	0	0	0	0	Unspecified	0	1	3	0	0	0	1	5	0
Work commitments	0	0	2	2	0	0	0	0	0	Work commitments	0	0	0	0	0	0	0	0	0

Supplementary Table 4: Study withdrawal reasons by treatment arm.

Reasons for exclusion from ConCorD-19 during screening Participants (n)

Unable to be contacted	736
Days of symptoms > 5	777
Asymptomatic	306
Isolating from household contacts	219
Hospitalized	177
Confirmation of COVID-19 took longer than 72 hours	35
Deceased	2
Ineligible medical condition or treatment	67
Less than 18 years old	54
Pregnant, or plans on becoming pregnant	32
Previously infected with COVID-19	36
Greater than 80 years old	3
All eligible household contacts currently infected	514
Does not live with eligible household contact	412
Not the first infection in the household	392
Does not live in the Santiago metropolitan area	20
Reasons for not participating in ConCorD-19	
Index case declined	835
Eligible household contact declined	196
Total	4813

Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.

Analyses outlined in SAP		Exclusions		Participants (n) included for analyses			
Analysis	Population	Reason	Participants (n)		IFN	SOC	
	Full study population			IC	172	169	
				EHC	177	165	
					CP-HC	80	81
					IHC	178	150
Primary 1 - Main	IC-INF at day 11	No visit	22	IC	159	164	
		Visit outside window	3	CP-HC	69	76	
Primary 1 – Sensitivity 1	IC-ITT at day 11	No visit	12	IC	159	164	
		Visit outside window	2				
Primary 1 – Sensitivity 2	IC-PP at day 11	No visit or protocol deviation	26	IC	146	164	
		Visit outside window	1				
Primary 2 – Main	EHC-ITT at day 11	No visit	20	EHC	166	156	
Primary 2 – Sensitivity 1	HC at day 11	No visit	37	EHC	166	156	
				IHC	168	143	

Primary 2 – Sensitivity 2	EHC-PP at day 11	No visit or protocol deviation	30		EHC	156	156
Exploratory Analyses		Exclusions					
Analysis	Population	Reason	Households (n)	Participants (n)			
Frequentist	Household contacts, COVID- 19 negative at study day 1	COVID-negative index case	33		EHC	164	142
		No household contacts at risk	49				
		Household contact COVID positive		43	IHC	129	104
Bayesian	Frequentist population, household size ≤ 7	Household size > 7	5	61	EHC	152	139
					IHC	113	104

Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis. IC: index case, EHC: Treatment eligible household contacts, CP-HC: COVID-19 positive household contacts, IHC: Treatment ineligible household contacts, IC-INF: IC & CP-HC, IC-ITT: Index case – intention to treat population, IC-PP: Index case – per protocol population, EHC-ITT: Treatment eligible household contacts – intention to treat population, HC: EHC and IHC, EHC-PP: Treatment eligible household contact – per protocol population.

Study period	Mean	Standard Deviation	95% Credible Intervals	
			Lower limit (2.5%)	Upper limit (97.5%)
1	-1.17	0.52	-2.23	-0.19
2	0.27	0.55	-0.80	1.36

Odds ratio for treatment with IFN

95% Credible Intervals

Study period	Mean	Standard Deviation	95% Credible Intervals	
			Lower limit (2.5%)	Upper limit (97.5%)
1	0.32	1.68	0.11	0.83
2	1.31	1.73	0.45	3.90

Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.

Study period	2.5%	25%	50%	Mean	75%	97.5%
1	0.009	0.059	0.085	0.085	0.110	0.159
2	-0.067	-0.028	-0.009	-0.009	0.010	0.048

Supplementary Table 8: Difference in probability of infection in each study period

irrespective of household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Study period	Household size	2.5%	25%	50%	Mean	75%	97.5%
1	2	-0.143	0.000	0.286	0.053	0.143	0.286
1	3	0.000	0.092	0.276	0.139	0.184	0.276
1	4	0.003	0.087	0.249	0.128	0.170	0.249

1	6	-0.120	0.030	0.326	0.103	0.189	0.326
1	7	-0.231	-0.077	0.308	0.024	0.077	0.308
2	2	-0.118	-0.059	0.075	-0.008	0.000	0.075
2	3	-0.085	-0.021	0.090	0.001	0.028	0.090
2	4	-0.130	-0.068	0.059	-0.037	-0.006	0.059
2	5	-0.128	-0.052	0.103	-0.013	0.027	0.103
2	6	-0.129	-0.015	0.254	0.059	0.117	0.254
2	7	-0.154	0.000	0.154	0.016	0.077	0.154

Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size. Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Household size	Number of households	Total contacts	Indirect contacts
2	42	42	0
3	61	64	27
4	80	84	89
5	46	58	59
6	19	29	30
7	6	14	12

Supplementary Table 10: Number of contacts at each household size.

Supplementary References

1. Goodrich B GJ, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3 ed2022.

